BusinessAdamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with DyskinesiaBy Nasdaq OMXApr 19, 2018, 9:30 AM UTC
BusinessAdamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis JournalBy Nasdaq OMXFeb 1, 2018, 9:05 PM UTC
BusinessEsperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination PillBy Nasdaq OMXNov 6, 2017, 9:30 PM UTC
BusinessEsperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic AcidBy Nasdaq OMXOct 2, 2017, 8:30 PM UTC
BusinessEsperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and EzetimibeBy Nasdaq OMXJun 26, 2017, 8:05 PM UTC
BusinessAdamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s DiseaseBy Nasdaq OMXApr 24, 2017, 1:06 PM UTC
BusinessAdamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual MeetingBy Nasdaq OMXApr 18, 2017, 4:08 PM UTC
BusinessAdamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual MeetingBy Nasdaq OMXMar 28, 2017, 5:38 PM UTC
